This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Arteritis, Giant Cell
and you are
over 50
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.

Provided treatments

  • Drug: Baricitinib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03026504. The sponsor of the trial is Matthew J Koster and it is looking for 15 volunteers for the current phase.
Official trial title:
Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study